Which tumors can be treated with pemetinib/dabotan?

Pemigatinib is a potent and selective oral inhibitor of fibroblast growth factor receptor (FGFR) subtypes 1/2/3. It is used to treat a variety of solid tumors. It blocks the growth and spread of cancer cells by blocking the FGFR-mediated signaling pathway in tumor cells. PemetinibThe original drug has been launched in China under the trade name of Dabotan/PEMAZYRE. Pemetinib is mainly used to treat the following conditions:

1. Cholangiocarcinoma (CCA): Pemetinib is indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma using fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells, and its incidence rate is increasing year by year. The emergence of pemetinib/pemetinib provides a new treatment option for these patients.

2. Myeloid/lymphoid neoplasms (MLN) with FGFR1 rearrangement: Pemetinib is suitable for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement. MLN with FGFR1 rearrangement is an extremely rare and aggressive blood cancer. The efficacy of pemetinib was excellent in these patients, bringing hope for their treatment.

In summary, pemetinib, as a potent and selective oral inhibitor againstFGFR isoforms 1/2/3, inhibits the growth and spread of cancer cells by blocking the FGFR-mediated signaling pathway in tumor cells. It excels in treating cholangiocarcinoma and rare blood cancers with FGFR1 rearrangements, providing patients with new treatment options. However, each patient's specific situation may be different, so a medical evaluation and discussion is required before using pemetinib to determine the most appropriate treatment option for the patient.